Clinical Scorecard: Evaluation of Various eGFR Formulas in Predicting 1-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients

At a Glance

Key Highlights

• Cystatin C–based eGFR classified more patients with impaired renal function than creatinine-based formulas.
• Moderate-to-severe renal dysfunction was associated with elevated 1-year MACE risk.
• Logistic regression showed the greatest discriminative ability for predicting MACE.
• Machine learning models demonstrated modest predictive performance compared to traditional methods.
• Renal function assessment is crucial for cardiovascular risk stratification.

Guideline-Based Recommendations

Diagnosis

• Evaluate renal function using eGFR equations based on creatinine and cystatin C.

Management

• Consider renal function in post-procedural management of patients undergoing PCI.

Monitoring & Follow-up

• Monitor renal function indicators alongside cardiovascular functional parameters.

Risks

• Recognize that renal impairment is linked to increased risks of mortality and cardiovascular events.

Patient & Prescribing Data

560 patients with coronary artery disease undergoing PCI.

Assessment of renal function is essential for optimizing outcomes post-PCI.

Clinical Best Practices

• Utilize both creatinine-based and cystatin C–based eGFR for comprehensive risk assessment.
• Incorporate machine learning techniques cautiously, as traditional models may suffice.

Related Resources & Content

• Study on renal dysfunction and cardiovascular prognosis